Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Sep 04, 2022 10:48am
194 Views
Post# 34940730

RE:RE:# of NR patients

RE:RE:# of NR patients

To complete my point, at 90 days if we end up excluding at least 10 -11patients ( 9 NR from 1st set, plus patient who died and #4 from PH1) who can be considered severely undertreated or anomalies, then we would say out of the remaining 28 optimized treated patients, we have 3 NR's  ( 13-10=3) .  Please correct me if wrong, but that is pretty damn good IMHO.  Already 35% CR at 360 days is damn good and better than All single agents including CG007 (28%). Plus we have 12% PR which can convert in part or all to CR.


enriquesuave wrote: Nice observations.  If we only look at the NR patients at 90 days, the include 1 NR fro PH1B ( pt had prior metastasis and not really eligible) 1 patient who died of HF ( had optimized treatment) 5 patients who were wrongly dropped from trial ( 1st set of 12 undertreated) plus 3 patients from remaining 7 of 1st set of 12 who never got an Optimized Treatment ( only 4 I believe got a second treatment which was optimized.  ( so over all 9 NR from 1st of 12 plus 1 from PH1 and patient who died).  That's 11 patients who should not really be included in trial data IMO, but are .  We are seeing improvement over time so this looks very good IMHO.  Also 4 more patients have been treated as we now stand at 45 patients total ( includes 3 from PH1). In May there was only 41 patients total.  7 now pending at 90 days.  Looking forward to Next update 

 

<< Previous
Bullboard Posts
Next >>